Simpson, Eric L. http://orcid.org/0000-0003-0853-0252
Kircik, Leon http://orcid.org/0000-0002-0831-2151
Blauvelt, Andrew http://orcid.org/0000-0002-2633-985X
Kallender, Howard http://orcid.org/0000-0001-5634-883X
Sturm, Daniel http://orcid.org/0009-0001-4413-8429
Wang, Mingyue
Eichenfield, Lawrence F. http://orcid.org/0000-0002-2760-0474
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies
https://doi.org/10.1007/s13555-024-01219-8
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
Funding for this research was provided by:
Incyte Corporation, Wilmington, DE, USA
Article History
Received: 30 April 2024
Accepted: 19 June 2024
First Online: 12 July 2024
Declarations
:
: Eric L. Simpson is an investigator for AbbVie, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, and Regeneron; and is a consultant with honorarium for AbbVie, Eli Lilly, Forte Bio, Galderma, Incyte, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and Valeant. Leon Kircik has served as an investigator, consultant, or speaker for AbbVie, Amgen, Anaptys, Arcutis, Dermavant, Eli Lilly, Glenmark, Incyte, Kamedis, LEO Pharma, L’Oreal, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and Taro. Andrew Blauvelt is a member and owner of Blauvelt Consulting and has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. Howard Kallender and Daniel Sturm are employees and shareholders of Incyte. Mingyue Wang (currently at Boehringer Ingelheim) was an employee of Incyte at the time of the study and is a shareholder of Incyte. Lawrence F. Eichenfield has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Amgen, Arcutis, Aslan, Bristol Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Target RWE, and UCB.
: These studies were conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. All patients provided written informed consent before enrollment. The protocols were approved by the relevant institutional review board or ethics committee at each study center (Supplementary Materials Tables and ).